Evidence map›Paper›PMID 35008578›Full record

ArticleInternational journal of molecular sciences2021

Akt Inhibition as Preconditioning Treatment to Protect Kidney Cells against Anoxia.

Nicolas Melis, Romain Carcy, Isabelle Rubera, Marc Cougnon, Christophe Duranton, Michel Tauc, Didier F Pisani

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. New Strategies Protecting from Ischemia/Reperfusion.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Nicolas MelisLaboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0001-7456-6232
Romain CarcyUniversité Côte d'Azur, CNRS, LP2M, 06103 Nice, France.
Isabelle RuberaUniversité Côte d'Azur, CNRS, LP2M, 06103 Nice, France.
Marc CougnonUniversité Côte d'Azur, CNRS, LP2M, 06103 Nice, France.
Christophe DurantonUniversité Côte d'Azur, CNRS, LP2M, 06103 Nice, France.
Michel TaucUniversité Côte d'Azur, CNRS, LP2M, 06103 Nice, France.ORCID 0000-0002-8383-9818
Didier F PisaniUniversité Côte d'Azur, CNRS, LP2M, 06103 Nice, France.ORCID 0000-0001-5879-8527
Centre National de la Recherche Scientifique · FRNational Cancer Institute · US

Funding

Agence Nationale de la Recherche ANR-19-CE18-0029/KIRI
6 · The paper itself

Abstract

Lesions issued from the ischemia/reperfusion (I/R) stress are a major challenge in human pathophysiology. Of human organs, the kidney is highly sensitive to I/R because of its high oxygen demand and poor regenerative capacity. Previous studies have shown that targeting the hypusination pathway of eIF5A through GC7 greatly improves ischemic tolerance and can be applied successfully to kidney transplants. The protection process correlates with a metabolic shift from oxidative phosphorylation to glycolysis. Because the protein kinase B Akt is involved in ischemic protective mechanisms and glucose metabolism, we looked for a link between the effects of GC7 and Akt in proximal kidney cells exposed to anoxia or the mitotoxic myxothiazol. We found that GC7 treatment resulted in impaired Akt phosphorylation at the Ser473 and Thr308 sites, so the effects of direct Akt inhibition as a preconditioning protocol on ischemic tolerance were investigated. We evidenced that Akt inhibitors provide huge protection for kidney cells against ischemia and myxothiazol. The pro-survival effect of Akt inhibitors, which is reversible, implied a decrease in mitochondrial ROS production but was not related to metabolic changes or an antioxidant defense increase. Therefore, the inhibition of Akt can be considered as a preconditioning treatment against ischemia.

Indexed as

AnimalsAntioxidantsCells, CulturedHypoxiaIschemic PreconditioningKidneyMethacrylatesMiceMitochondriaPhosphorylationProtective AgentsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktReactive Oxygen SpeciesReperfusion InjuryThiazolesAntioxidantsMethacrylatesmyxothiazolProtective AgentsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktReactive Oxygen SpeciesThiazoleseIF5AGC7ischemiamitochondriaROStriciribine

Identifiers

PMID35008578
PMCPMC8745656
OpenAlexW4200260855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.